Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters

European Journal of Medicinal Chemistry

Volumn 45, Issue 5, 2010, Pages 1703-1716

  Moraski, Garrett C ^a   Chang, Mayland ^a   Villegas Estrada, Adriel ^a   Franzblau, Scott G ^b   Möllmann, Ute ^c   Miller, Marvin J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Aryl oxazole; Aryl oxazoline; Benzyl ester; Mycobactins; Structure activity relationships; Tuberculosis agents

Indexed keywords

AMIDE; BENZYL 2 (2 CHLOROPHENYL)OXAZOLE 4 CARBOXYLATE; BENZYL 2 (4 FLUORO 3 NITROPHENYL) 4,5 DIHYDROOXAZOLE 4 CARBOXYLATE; BENZYL 2 (4 FLUORO 3 NITROPHENYL)OXAZOLE 4 CARBOXYLATE; BENZYL 2 (4 METHOXYPHENYL)OXAZOLE 4 CARBOXYLATE; BENZYL 2 [2 (BENZYLOXY)PHENYL] 4,5 DIHYDROOXAZOLE 4 CARBOXYLATE; BENZYL 2 [2 (BENZYLOXY)PHENYL]OXAZOLE 4 CARBOXYLATE; BENZYL 2 PHENYLOXAZOLE 4 CARBOXYLATE; BENZYL 4,5 DIHYDRO 2 PHENYLOXAZOLE 4 CARBOXYLATE; BENZYL DERIVATIVE; OXAZOLE DERIVATIVE; OXAZOLINE DERIVATIVE; RIFAMPICIN; SERINE; THREONINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DISEASE MODEL; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ESTERS; MICE; MICE, INBRED BALB C; MOLECULAR CONFORMATION; MYCOBACTERIUM TUBERCULOSIS; OXAZOLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 77949487512     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.12.074     Document Type: Article

References (36)

1. Anti-tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997 (1997), WHO WHO/TB/97.229
2. Daniel T.M., Bates J.H., and Downes K.A. History of tuberculosis. In: Bloom B. (Ed). Tuberculosis: Pathogenesis, Protection, and Control (1994), ASM Press, Washington, D.C 13-24
3. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2008 (2008), WHO WHO/HTM/TB/2008.393
4. Basso L.A., and Blanchard J.S. Adv. Exp. Med. Biol. 456 (1998) 115-144
5. Bradford W.Z., and Daley C.L. Infect. Dis. Clin. North Am. 12 (1998) 157-172
6. Bastian I., and Colebunders R. Drugs 58 (1999) 633-666
7. Cohn D.L., Bustreo F., and Raviglione M.C. Clin. Infect. Dis. 24 (1997) S121-S130
8. Snider D.E., and Castro K.G. N. Engl. J. Med. 338 (1998) 1689-1690
9. Tuberculosis: A Global Emergency 14 (1993), World Health Forum p. 438
10. Dorman S.E., and Chaisson R.E. Nat. Med. 13 (2007) 295-298
11. Girijavallabhan V., and Miller M.J. In: Crosa J.H., Mey A.R., and Payne S.M. (Eds). Therapeutic Uses of Iron(III) Chelators and Their Antimicrobial Conjugates. In Iron Transport in Bacteria (2004) 413-433 (Chapter 27)
12. Roosenberg II J.M., Lin Y.-M., Lu Y., and Miller M.J. Curr. Med. Chem. 7 (2000) 159-197
13. Lu Y., and Miller M.J. Bioorg. Med. Chem. 7 (1999) 3025-3038
14. Vergne A.F., Walz A.J., and Miller M.J. Nat. Prod. Rep. 17 (2000) 99-116
15. Miller M., Zhu H., Xu Y., Wu C., Walz A., Vergne A., Roosenberg J., Moraski G., Minnick A., McKee-Dolence J., Hu J., Fennell K., Dolence K., Dong L., Franzblau S., Malouin F., and Mollmann U. Biometals 22 (2009) 61-75
16. Xu Y., and Miller M.J. J. Org. Chem. 63 (1998) 4314-4322
17. Hu J., and Miller M.J. Am. Chem. Soc. 119 (1997) 3462-3468
18. Moraski G., Miller M.J., and Franzblau S.G. Franzblau, Hetrocycles 80 (2010) 977-988
19. 7.7 μM is the average value from multiple tests (15 in total) of ND-005859 in the GAST (low iron Tween 80 containing media) run in Scott Franzblau's lab at the University of Illinois at Chicago. The MIC has ranged from 2.2 μM to 13.7 μM in this assay.
20. Snow G.A. Bacteriol. Rev. 34 (1970) 99-125
21. Assay data from level two testing at the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) in Bethesda, MD.
22. Ferreras J.A., Ryu J.-S., Lello F.D., Tan D.S., and Quadri L.E. Nat. Chem. Biol. 1 (2005) 29-32
23. Somu R.V., Boshoff H., Qiao C., Bennett E.M., Barry III C.E., and Aldrich C.C. J. Med. Chem. 49 (2006) 31-34
24. Miethke M., Bisseret P., Beckering C.L., Vignard D., Eustache J., and Marahiel M.A. FEBS J. 273 (2006) 409
25. Vannada J., Bennett E.M., Wilson D.J., Boshoff H., Barry III C.E., and Aldrich C.C. Org. Lett. 21 (2006) 4707-4710
26. Barry III C.E., Slayden R.A., Sampson A.E., and Lee R.E. Biochem. Pharmacol. 59 (2000) 221-231
27. Phillips A.J., Uto Y., Wipf P., Reno M.J., and Williams D.R. Org. Lett. 2 (2000) 1165-1168
28. Williams D.R., Lowder P.D., Gu Y.G., and Brooks D.A. Tetrahedron Lett. 38 (1997) 331-334
29. Rakesh, Sun D., Lee R.B., Tangallapally R.P., and Lee R.E. Eur. J. Med. Chem. 44 (2009) 460-472
30. Lilienkampf A., Mao J., Wan B., Wang Y., Franzblau S.G., and Kozikowski A.P. J. Med. Chem. 52 (2009) 2109-2118
31. Boshoff H.I., Myers T.G., Copp B.R., NcNeil M.R., Wilson M.A., and Barry III C.E. J. Biol. Chem. 279 (2004) 40174-40184
32. Collins L., and Franzblau S.G. Antimicrob. Agents Chemother. 41 (1997) 1004-1009
33. De Voss J.J., Rutter K., Schroeder B.G., Su H., Zhu Y., et al. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1252-1257
34. S.H. Cho, B. Wan, W. Di, C.H. Hwang, S.G. Franzblau, Keystone Symposium: Tuberculosis: Integrating Host and Pathogen Biology: Whistler, British Columbia, Canada, 2005.
35. Falzari K., Zhou Z., Pan D., Liu H., Hongmanee P., and Franzblau S.G. Antimicrob. Agents Chemother. 49 (2005) 1447-1454
36. Simulated gastric fluid and simulated intestinal fluid. In The United States Pharmacopeia 23, The National Formulary 18 (1995), The United States Pharmacopeial Convention, Inc., Rockville, MD pp. 2053